Corvus Pharmaceuticals(DE:C17)
€10.13-0.07 (-0.74%)
DE:C17
Corvus Pharmaceuticals financials statements
€10.13
At close:-0.07 (-0.74%)
Corvus Pharmaceuticals (C17) Ratios
0 Followers
Corvus Pharmaceuticals Ratios
DE:C17's free cash flow for Q3 2026 was $-12.28M. For the 2026 fiscal year, DE:C17's free cash flow was decreased by $-66.00K and operating cash flow was $-12.21M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 6.21 | 1.54 | 4.07 | 4.06 | 7.36 |
| Quick Ratio | 6.21 | 1.54 | 4.07 | 4.06 | 7.36 |
| Cash Ratio | 0.49 | 0.25 | 1.84 | 1.22 | 6.55 |
| Solvency Ratio | -1.53 | -1.71 | -3.91 | -3.38 | -3.48 |
| Operating Cash Flow Ratio | -3.50 | -0.72 | -3.48 | -2.51 | -3.79 |
| Short-Term Operating Cash Flow Coverage | -81.38 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 48.30M | $ 18.07M | $ 21.09M | $ 31.54M | $ 59.02M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.02 | 0.03 | 0.04 | 0.03 |
| Debt-to-Equity Ratio | 0.02 | 0.03 | 0.04 | 0.05 | 0.04 |
| Debt-to-Capital Ratio | 0.02 | 0.03 | 0.03 | 0.04 | 0.04 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.16 | 2.12 | 1.18 | 1.22 | 1.13 |
| Debt Service Coverage Ratio | -37.66 | 0.00 | 0.00 | 0.00 | -2544.67 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -2575.33 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.01 | 0.02 | 0.03 | 0.06 | 0.09 |
| Net Debt to EBITDA | 0.24 | 0.12 | 0.48 | 0.33 | 1.57 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 35.57% | 226.13% | 115.47% | 126.84% | 111.94% |
| Return on Assets (ROA) | -21.49% | -90.40% | -59.34% | -60.53% | -39.51% |
| Return on Equity (ROE) | -24.97% | -191.27% | -69.87% | -73.61% | -44.50% |
| Return on Capital Employed (ROCE) | -69.60% | -82.22% | -60.51% | -56.65% | -38.72% |
| Return on Invested Capital (ROIC) | -69.15% | -81.77% | -58.43% | -55.46% | -38.32% |
| Return on Tangible Assets | -21.49% | -90.40% | -59.34% | -60.53% | -39.51% |
| Earnings Yield | -2.51% | -19.09% | -31.98% | -104.39% | -42.87% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -8659.19 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 8659.19 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.42 | -0.42 | -0.50 | -0.58 | -0.88 |
| Free Cash Flow Per Share | -0.42 | -0.42 | -0.50 | -0.59 | -0.88 |
| Dividend Paid and CapEx Coverage Ratio | -188.49 | 0.00 | -703.97 | -100.46 | -7343.00 |
| Capital Expenditure Coverage Ratio | -188.49 | 0.00 | -703.97 | -100.46 | -7343.00 |
| Operating Cash Flow Coverage Ratio | -35.00 | -22.66 | -17.42 | -10.39 | -10.07 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -5.42% | -7.79% | -28.36% | -68.97% | -36.40% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -40.53 | -5.24 | -3.13 | -0.96 | -2.33 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 9.93 | 10.02 | 2.18 | 0.71 | 1.04 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -18.44 | -12.83 | -3.53 | -1.45 | -2.75 |
| Price-to-Operating Cash Flow Ratio | -18.54 | -12.83 | -3.53 | -1.46 | -2.75 |
| Price-to-Earnings Growth (PEG) Ratio | 0.50 | -0.06 | 0.09 | 0.07 | -0.01 |
| Enterprise Value Multiple | -39.82 | -5.12 | -3.15 | -0.90 | -1.08 |
| Enterprise Value | 604.39M | 318.65M | 73.28M | 29.01M | 41.06M |
| EV to EBITDA | -39.82 | -5.12 | -3.15 | -0.90 | -1.08 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -18.33 | -12.53 | -3.06 | -1.06 | -1.12 |
| EV to Operating Cash Flow | -18.43 | -12.53 | -3.06 | -1.07 | -1.12 |
| Tangible Book Value Per Share | 0.78 | 0.53 | 0.81 | 1.21 | 2.32 |
| Shareholders’ Equity Per Share | 0.78 | 0.53 | 0.81 | 1.21 | 2.32 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.19 | -1.02 | -0.56 | -0.89 | -1.03 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.15 | 1.27 | 1.12 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 2.15 | 0.41 | 0.89 | 0.65 | 0.85 |
Currency in USD
